TY - JOUR
T1 - SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors
T2 - A comprehensive multidisciplinary team approach
AU - Werner, R. A.
AU - Bluemel, Christina
AU - Lassmann, M.
AU - Kudlich, T.
AU - Higuchi, T.
AU - Lopci, Egesta
AU - Allen-Auerbach, M.
AU - Colletti, Patrick M.
AU - Rubello, Domenico
AU - Zatelli, M. C.
AU - Herrmann, Ken
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/5/22
Y1 - 2015/5/22
N2 - The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.
AB - The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.
KW - PET-based patient-tailored
KW - SPECT-based patient-tailored
KW - neuroendocrine tumors
KW - tailored treatment
KW - team approach
UR - http://www.scopus.com/inward/record.url?scp=84928421672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928421672&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000000729
DO - 10.1097/RLU.0000000000000729
M3 - Review article
C2 - 25642915
AN - SCOPUS:84928421672
SN - 0363-9762
VL - 40
SP - e271-e277
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 5
ER -